Cellular and molecular defects in a patient with Hermansky-Pudlak syndrome type 5

Joshi Stephen\(^1\)
Tadafumi Yokoyama\(^1\)
Nathanial J. Tolman\(^2\)
Kevin J. O’Brien\(^1\)
Elena-Raluca Nicoli\(^2\)
Brian P. Brooks\(^3\)
Laryssa Huryn\(^3\)
Steven A. Titus\(^4\)
David R. Adams\(^2,5\)
Dong Chen\(^6\)
William A. Gahl\(^1,2,5\)
Bernadette R. Gochuico\(^1\)**
May Christine V. Malicdan\(^2,5\)**

\(^1\) Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America, \(^2\) NIH Undiagnosed Diseases Program, Common Fund, Office of the Director, National Institutes of Health, Bethesda, Maryland, United States of America, \(^3\) Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States of America, \(^4\) Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America, \(^5\) Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America, \(^6\) Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, United States of America

\(*\) gochuicb@mail.nih.gov

OPEN ACCESS

Citation: Stephen J, Yokoyama T, Tolman NJ, O’Brien KJ, Nicoli ER, Brooks BP, et al. (2017) Cellular and molecular defects in a patient with Hermansky-Pudlak syndrome type 5. PLoS ONE 12(3): e0173682. https://doi.org/10.1371/journal.pone.0173682

Editor: Ruben Claudio Aguilar, Purdue University, UNITED STATES

Received: April 27, 2016
Accepted: February 24, 2017
Published: March 15, 2017

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the Intramural Research Programs of the National Human Genome Research Institute and the National Eye Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.

Competing interests: The authors have no competing interests to declare.

Abstract

Hermansky-Pudlak syndrome (HPS) is a heterogeneous group of genetic disorders typically manifesting with tyrosinase-positive oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis, in some subtypes. Most HPS subtypes are associated with defects in Biogenesis of Lysosome-related Organelle Complexes (BLOCs), which are groups of proteins that function together in the formation and/or trafficking of lysosomal-related endosomal compartments. BLOC-2, for example, consists of the proteins HPS3, HPS5, and HPS6.

Here we present an HPS patient with defective BLOC-2 due to a novel intronic mutation in HPS5 that activates a cryptic acceptor splice site. This mutation leads to the insertion of nine nucleotides in-frame and results in a reduced amount of HPS5 at the transcript and protein level. In studies using skin fibroblasts derived from the proband and two other individuals with HPS-5, we found a perinuclear distribution of acidified organelles in patient cells compared to controls. Our results suggest the role of HPS5 in the endo-lysosomal dynamics of skin fibroblasts.

Introduction

Hermansky-Pudlak syndrome (HPS) is a group of related autosomal recessive disorders due to mutations in genes involved in intracellular membrane and protein trafficking. HPS was first reported in 1959 by Hermansky and Pudlak, who described two patients with oculo-cutaneous albinism and prolonged bleeding [1]. Currently, OMIM (On line Mendelian Inheritance of Man) describes 10 genetic subtypes of HPS: type 1 (due to mutations in \(HPS1\)), type 2 (due to mutations in \(HPS2\)), type 3 (due to mutations in \(HPS3\)), type 4 (due to mutations in \(HPS4\)), type 5 (due to mutations in \(HPS5\)), type 6 (due to mutations in \(HPS6\)), type 7 (due to mutations in \(HPS7\)), type 8 (due to mutations in \(HPS8\)), type 9 (due to mutations in \(HPS9\)), and type 10 (due to mutations in \(HPS10\)).
(AP3B1), type 3 (HPS3), type 4 (HPS4), type 5 (HPS5), type 6 (HPS6), type 7 (DTNBP1), type 8 (BLOC1S3), type 9 (BLOC1S6), and type 10 (AP3D1) [2]. Products of 8 of the 10 HPS genes operate in distinct protein complexes called the Biogenesis of Lysosome-related Organelle Complexes (BLOCs) that function together in the formation and/or trafficking of lysosome-related endosomal compartments [3]; the products of AP3B1 and AP3D1 are subunits of adaptor protein complex-3 (AP-3), which plays a role in enriching cargo proteins in vesicles for transport through the intracellular endosomal/lysosomal pathway [4].

The trans Golgi network is the first-round sorting center of newly synthesized molecules destined for the lysosome, melanosome, and other lysosome-related organelles (LRO) [5]. Golgi-derived proteins destined for LROs and late endosomes/lysosomes, and proteins of the recycling endosomal pathway are also sorted in early endosomes and their associated tubules [3]. HPS protein complexes (eg: BLOCs) contribute to the maturation of organelles by regulating the delivery of molecules to LROs. BLOC-1 is a multimeric complex including HPS7, HPS8 and HPS9 [6]; BLOC-2 comprises HPS3, HPS5 and HPS6 [7], and HPS1 and HPS4 form BLOC-3 [8]. Human HPS subtypes with mutations in the same BLOC manifest similar phenotypes, and the severity of the phenotype varies according to the type of BLOC defect [6]. For example, pulmonary fibrosis is associated with HPS types 1 and 4 (BLOC-3), while neutropenia, absence of lytic granules in lymphocytes, immunodeficiency, and interstitial fibrosis are characteristics of HPS type 2 [3].

In this study, we report a patient with a milder form of HPS resulting from defective BLOC-2 due to a novel intronic mutation in the HPS5 gene. We also describe the consequences of this mutation at the cellular and molecular levels.

Materials and methods

Written informed consent was provided for clinical protocols 95-HG-0195 (“Clinical and Basic Investigations into Hermansky-Pudlak Syndrome”) and 04-HG-0211 (“Procurement and Analysis of Specimens from Individuals with Pulmonary Fibrosis”), which were approved by the National Human Genome Research Institute (NHGRI) Institutional Review Board. Clinical evaluations, including high-resolution computed tomography scans of the chest and bronchoscopy with lavage, were performed at the National Institutes of Health (NIH) Clinical Center as previously described [9].

Targeted panel sequencing

Exome sequencing was performed at the Casey Eye Institute Molecular Diagnostic Laboratory using Pigmentation SmartPanel (v3; gene list is available upon request). Direct testing for mutations in the genes of the Pigmentation Smart Panel was performed by PCR amplification and Next Generation Sequencing. PCR primer sets were printed on the SmartPanel chips. Each primer set is duplicated on the chips in order to avoid random PCR failure. Any low coverage region (<100X) was covered afterwards by PCR and Sanger sequencing. Identified mutations and novel variants were confirmed by Sanger sequencing. For dideoxy sequencing, specific primers were designed (primer sequences available upon request) to amplify the desired regions. Direct sequencing of the PCR amplification products was performed using BigDye 3.1 Terminator chemistry (Applied Biosystems, Austin, Texas, USA) and separated on an ABI 3130xl genetic analyzer (Applied Biosystems, Foster city, CA, USA). Data were evaluated using Sequencher v5.0 software (Gene Codes Corporation, Ann Arbor, MI).

Cell culture

Fibroblasts were cultured from forearm skin biopsies and grown in high-glucose (4.5 g/l) DMEM supplemented with 15% FBS, 2 mM L-glutamine, nonessential amino acid solution,
and penicillin-streptomycin. Normal adult human dermal fibroblasts (ATCC® PCS-201-012™) served as controls.

Reverse transcriptase PCR, cDNA analysis and qPCR
Total RNA was isolated from the skin-derived fibroblast culture using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. RNA concentration and purity were assessed and first strand cDNA was synthesized using a high capacity RNA-to-cDNA kit (Applied Biosystems). Reverse transcriptase reaction products were amplified using specific primers (forward 5’-AAGAAGGCTGGAAGCAGG-3’ and reverse 5’-TCCCTAGACCTGG-3’) and loaded into 2% agarose gel. Sanger sequencing of the excised bands was performed as mentioned above. Quantitative real-time PCR (qPCR) was performed using primers specific for the three different isoforms of HPS5. cDNA derived from both patient and control was amplified using Power SYBR Green PCR master mix (Applied Biosystems, Woolston, Warrington, UK) and the real-time amplification was monitored using Bio-Rad qPCR machine (CFX96 Touch Real Time PCR detection system, Philadelphia, PA, USA) with standard qPCR parameters. Results were normalized with expression of the housekeeping gene POLR2A and analyzed using the comparative C_T method [10]

Western blotting
Fibroblasts were grown to confluency in T75 flasks, trypsinized, and pelleted. Total protein from cell pellets was obtained by lysing in RIPA buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Sigma-Aldrich). The total amount of protein in each sample was determined using the BCA assay kit (Pierce, Rockford, IL.). 20μg of the proteins were electrophoresed on a 4–12% Bis-Tris or 3–8% Tris-Acetate gel (Life Technologies) with MOPS, MES, or Tris-Acetate buffer (Life Technologies) and blotted onto a PVDF or nitrocellulose membrane (Invitrogen, Carlsbad, CA, USA). Membranes were blocked with Li-Cor blocking buffer (Li-Cor Biosciences) for one hour, and then incubated overnight at 4°C with the following antibodies specific for each protein: rabbit polyclonal anti-HPS5 Ab (Proteintech), rabbit polyclonal anti-HPS6 Ab (Origene), rabbit polyclonal anti-HPS3 Ab (Proteintech), rabbit polyclonal anti-HPS2 Ab (Proteintech), rabbit polyclonal anti-HPS4 Ab (Proteintech), mouse monoclonal anti-HPS7 Ab (Santa Cruz Biotech), rabbit polyclonal anti-Rab11 (Abcam), mouse monoclonal anti-β-actin Ab (CST), rabbit polyclonal anti-β-actin Ab (Abcam), and mouse monoclonal anti-β-actin Ab (Sigma). After 3 washes in PBS with 0.1% Tween-20, membranes were incubated with the appropriate secondary antibodies (Li-Cor Biosciences, Lincoln, NE). The target bands were scanned and visualized using Odyssey® imaging system (Li-COR).

Immunofluorescence microscopy
Fibroblasts were cultured in chamber slides for 72 hrs after passage and washed with PBS twice, fixed with 4% PFA at room temperature for 15 min, and permeabilized using 0.1% saponin. Slides were blocked with 5% donkey serum and 1% BSA for 30 min, incubated in primary Abs overnight at 4°C followed by incubation in appropriate secondary Abs, mounted in Vectorshield solution containing DAPI (Vector Laboratories). Antibodies used for this method were: rabbit polyclonal anti-EEA1 Ab (Abcam), rabbit polyclonal anti-Rab11 Ab (Abcam), rabbit monoclonal anti-Rab7 AB (Cell Signaling), mouse monoclonal anti-CD63/LAMP3 Ab (H5C6; Developmental Studies, Hybridoma Bank), and Alexa fluor secondary donkey anti-rabbit/mouse Abs (Invitrogen). Cells were imaged with a Zeiss 510 META confocal laser-scanning microscope. For quantification of CD63 staining, 6000 cells/well were seeded in 96-well black/clear bottom plates and stained with anti-CD63/LAMP3 Ab, followed by donkey anti-mouse
Alexa fluor secondary antibody. Cells were then imaged on the InCell 2200 Analyzer and quantified as described elsewhere [11].

**LysoTracker assay**

LysoTracker red dye stains acidic cellular environment and visualizes acidic late endosomes and lysosomes. 6000 cells/well were seeded in 96-well black/clear bottom plates and stained using LysoTracker Red dye (L-7538, Life Technologies), and imaged as above using the InCell 2200 Analyzer.

**Statistical analysis**

Data shown are ± standard deviation or standard error of the mean as noted. Student’s t-test was performed to analyze significance of difference between means (GraphPad Prism, San Diego, CA).

**Results**

**Clinical report**

The patient is a 27-year-old Turkish man evaluated at the NIH Clinical Center for oculocutaneous albinism. He had mild hypopigmentation, nystagmus, and impaired visual acuity, but could read with corrective lenses. He noted easy bruising and prolonged bleeding following extractions of his teeth, and had a history of recurrent epistaxis; laser surgery decreased the frequency of his epistaxis. He never received medications to treat excessive bleeding or transfusions of blood products. He had no history of unusual infections, dyspnea, cough, abdominal pain, hematochezia, or abnormal bowel movements. His parents were first cousins but, although his sister, paternal uncle, and several first cousins had albinism, there was no known family history of HPS.

On physical examination, the patient had fair skin with some degree of sun tanning. His hair color was a medium to dark brown (Fig 1A). He had nystagmus, a V-pattern exotropia, and best corrected visual acuity of 20/125 bilaterally. Ophthalmologic examination revealed iris trans-illumination and a fundus with minimal retinal pigmentation compared to normal (Fig 1B). He also had peripapillary atrophy in the setting of high myopia. Optical coherence tomography demonstrated a poorly developed fovea consistent with foveal hypoplasia and visual evoked potential testing revealed crossing changes typically seen in patients with albinism. Pulmonary, cardiac, abdominal and neurological physical examination findings were normal.

Laboratory testing revealed normal chemistries, serum glucose, and liver function tests. Blood urea nitrogen and serum creatinine were normal, and 24-hour creatinine clearance was 156 ml/minute [normal range 90–125 ml/minute]. Complete blood count showed normal white blood cell count and differential, hemoglobin, and hematocrit; platelet count was 200 K/ul [normal range 161–347 K/ul]. Prothrombin time and activated partial thromboplastin time were normal. Electrocardiogram demonstrated sinus rhythm, and echocardiogram showed normal ventricular wall motion and no evidence of pulmonary hypertension.

Given the history of oculocutaneous albinism, nystagmus and tendency for bleeding, the patient was evaluated for HPS. Thin section electron microscopy images showed that the patient’s platelets have no gross abnormalities in overall granule content (Fig 1C). Whole mount transmission electron microscopy of platelets demonstrated absent dense bodies or delta granules (Fig 1D), consistent with the diagnosis of HPS. Pulmonary function testing revealed a forced vital capacity 109% of predicted and diffusion capacity 73% of predicted.
Oxygen saturations remained 99% throughout a six-minute walk test. High-resolution computed tomography scan of the chest showed no evidence of interstitial lung disease or ground glass opacification (Fig 1E, left panel). Bronchoalveolar cell differential count showed 93% alveolar macrophages, 5% lymphocytes, and 2% polymorphonuclear leukocytes. Imaging of stained bronchoalveolar cells revealed 16.5% (46/300 cells) of total to be foamy alveolar macrophages (Fig 1E, right panel). We analyzed the morphology of alveolar macrophages from an adult patient with HPS-1, who was closely matched for age and gender with our patient. We found that 18 (6.4%) of 307 alveolar macrophages were foamy in this patient with HPS-1, who did not have interstitial lung disease but is at high risk for future development of pulmonary fibrosis.

**Mutation identification**

Genes associated with skin pigmentation were screened using targeted exome sequencing. Variants identified were filtered using the databases of dbSNP, ClinSeq and the Exac
consortium (Broad Institute) with a minor allele frequency less than 0.05. Autosomal recessive model filter was employed due to the history of third degree consanguinity. Final analysis revealed a homozygous mutation, NM_181507.1; c.285-10A>G, in intron 4 of the HPS5 gene; which was confirmed by Sanger validation (Fig 2A). This variant is reported in online Exac database (http://exac.broadinstitute.org/variant/11-18332490-T-C) as a heterozygous change with an allele frequency of 0.0001. No healthy homozygotes were reported for this variant. According to splice prediction softwares (NetGene2 server and Alamut), the variation is predicted to activate a cryptic acceptor splice site nine nucleotides before the usual acceptor site of intron 4. Parental DNA was unavailable. To confirm the prediction of altered splicing, we amplified patient cDNA derived from dermal fibroblasts using specific primers flanking exon 4 and exon 5. Sanger sequencing of the products revealed an insertion of nine nucleotides.
**Fig 3. Cellular distribution of lysosomes.**

A. Distribution pattern CD-63 (green) in three HPS-5 patients including proband. Phalloidin (red) highlights cell boundary and DAPI (blue) stains nucleus. Upper panel shows lower magnification images showing perinuclear accumulation of CD63 in patients. Lower
from the intronic region into the coding frame (Fig 2A), which is predicted to result in an in-frame insertion of three amino acids, serine, cysteine and serine (NP_852608.1; p.Ser95_Gln96insSerCysSer) in the highly conserved domain of HPS5.

**HPS5 expression in fibroblasts**

*HPS5* has three main types of splice variants (Genbank), and the expression of each varies according to the type of tissue. At the transcript level, the mutation lies in the coding region of the longest isoform (variant 1; NM_181507.1), while the mutation resides in the 5'UTR of the two shorter isoforms (variant 2; NM_007216.3, variant 3; NM_181508.1). Since the position of the patient’s mutation varies among transcripts, we measured the expression of each isoform of *HPS5* using isoform-specific primers. Variants 1, 2, and 3 showed significantly decreased transcript levels to about 40%, 72% and 65% of normal, respectively (p <0.01, p <0.05, and p <0.01, respectively) (Fig 2B). Western blot analysis using a polyclonal antibody showed severely reduced HPS5 protein levels in the proband and two previously reported HPS-5 patients with loss-of-function mutations in *HPS5* [HPS5-1 (c.2593C>T; p.R865 and c.2624delT; p.L875Cfs20) [12] and HPS5-2 (c.302_305delTTTG; p.V101Gfs3 and c.1634+1G>A) [13]] compared to two separate controls (Fig 2C and S1 Fig). Evaluation of other BLOC-2 partners (HPS3 and HPS6) showed slightly reduced expression of HPS6 only in the proband (Fig 2C and S1 Fig). We also checked for the unaffected HPS complexes (HPS4 for BLOC-3, HPS7 for BLOC-1, and HPS2 for Adaptor Protein (AP)-3 complex) and found similar expression levels between HPS-5 patients and controls for all the proteins checked (S1 Fig).

**Expression and distribution of endo-lysosomal markers**

BLOC-2 participates in LRO biogenesis, such as melanosome and endosome maturation. Using patient-derived fibroblasts from three HPS-5 patients including the proband, we assessed the expression and distribution of early (EEA1), late (Rab7) and recycling (Rab11) endosomes and lysosomes (CD63). We found no difference in the distribution of EEA1 and Rab7 between control and patient cells (S2A Fig). Rab11 staining showed diffuse distribution through control and patient fibroblasts and suggested decreased fluorescent intensity in individuals with HPS-5 (S2A Fig). However, immunoblotting did not show a consistent reduction of Rab11 in HPS5 patients compared to two different controls (S2B and S2C Fig). The cellular distribution pattern of CD63 staining appeared to be altered in patients.: The CD63 signal is scattered throughout the cytoplasm in control and patient cell lines, while in patient cells this marker appeared less in the periphery of the cells and seemed to accumulate more in the perinuclear region when compared to controls (Fig 3A). Overall CD-63 intensity was not significantly different between patients and controls when cells were stained in a 96-well format for quantification (Fig 3B) Due to altered distribution of lysosome marker (CD63) by immunofluorescence, we next used LysoTracker dye staining to further assess the maturation and location of acidic organelles, including lysosomes, in individuals with HPS-5. We found these acidic organelles to be predominately around the nucleus in patient cells, in contrast to their more diffuse distribution in control cells (Fig 4A). However, the overall staining intensity was not significantly different between the two (Fig 4B).
Fig 4. LysoTracker assay. LysoTracker red dye staining shows the distribution of acidic organelles including mature lysosomes of two HPS-5 patients, including the proband, compared to control. Cell boundaries are marked with white dotted line. Scale bar represents 200 px (pixels).
Discussion

HPS-5 is a rare subtype of HPS, with only eleven patients reported in the literature (Table 1). Our patient’s clinical manifestations of oculocutaneous albinism and bleeding are similar to those reported in other individuals with HPS-5. Our patient is an adult, and his evaluation showed no evidence of interstitial lung disease or pulmonary fibrosis. Notably, some of his alveolar macrophages appeared foamy. Although alveolar macrophages are foamy and activated in patients with HPS-1, this is the first report of bronchoalveolar lavage cells from a patient with HPS-5, thus contributing a novel view of the clinical management for HPS. As of now, HPS-5 patients, unlike patients with HPS-1, do not develop the fatal complication of pulmonary fibrosis. Although this patient did not have clinical evidence of lung disease, analysis of his bronchoalveolar lavage cells identified foamy alveolar macrophages, which resemble those observed in patients with HPS-1 and may indicate a response to a pro-fibrotic alveolar milieu. Our report suggests that clinicians should be vigilant in evaluating for possible lung disease in patients with HPS-5.

Except for two missense mutations (p.Leu624Arg and p.Thr1098Ile), all the pathogenic variants previously reported in \textit{HPS5} were deleterious frameshift mutations (Table 1). In this study we report a novel in-frame insertion of three amino acids in the N-terminal region of HPS5. Unlike the reported cases, this mutation is found in an early coding region of the longest HPS5 isoform (NM\_181507.1), and in the 5'UTR of the other shorter isoforms (NM\_181508.1 and NM\_007216.3). qPCR revealed decreased expression of all three isoforms correlating with our Western results (Fig 2B and 2C). BLOC-2, which is composed of HPS5, HPS3 and HPS6, has a role in LRO biogenesis in melanosome and endosome maturation [7] and likely plays a role in the transition between stage II and stage III of melanosome biogenesis, perhaps through its role targeting cargo delivery to the melanosome [14, 15]. Given the availability of dermal fibroblasts from this patient, we focused on the endo-lysosomal pathway in his cultured skin fibroblasts. HPS affects the biogenesis of lysosomes and lysosome-related organelles, while BLOC-2, specifically, has been shown to associate with early endosomal tubules. Thus, we wanted to investigate any aberrant dynamics in the endo-lysosomal system that may be present[14]. Our confocal microscopy results showed that the distribution of early (EEA1) and late (Rab7) endosomal markers is unaffected in the three HPS-5 patients (S2A Fig). Recycling endosome (Rab11) intensity was low in all three HPS5 patient tested, despite being normally distributed throughout the cell (S2A Fig). The lysosomal marker CD-63, was found to be localized predominantly around the nucleus (Fig 3) in patient cells, consistent with an earlier finding by Huizing et al [12]. This finding was further supported by the perinuclear distribution of acidic organelles, including mature lysosomes, that are stained with LysoTracker dye (Fig 4). Although CD63 staining seems to be more concentrated around the nucleus, a robust conclusion cannot be made by quantifying immunofluorescence alone. Future studies, such as organelle labeling, may help in this regard. In the past, Dennis et al. reported a similar nuclear accumulation of tyrosinase (TYR) and TYR-related protein 1, both melanosomal proteins, in BLOC-2-deficient mice and proposed a role for BLOC-2 in targeting endosomal tubules to melanosomes [15]. Taken together, our study suggests a role for BLOC-2 in endosome-mediated lysosomal maturation and processing in addition to its previously reported involvement in the melanosomal pathway.
### Table 1. *HPS5* mutations reported in the literature.

| Patient | Age in years | Sex | Ancestry | Allele 1 | Allele 2 | HPS5 mRNA expression in fibroblasts | HPS5 Protein expression in fibroblasts | Nystagmus onset | Eye color | Fundus | Ref |
|---------|--------------|-----|----------|----------|----------|-------------------------------------|----------------------------------------|----------------|----------|--------|-----|
| 1       | 3            | M   | Turkish  | c.2026_2029del;p. Val876Metfs*8 | c.2026_2029del;p. Val876Metfs*8 | ND                                  | NP                                      | ND             | ND       | ND     | [16]|
| 2       | 10           | M   | 1. English 2, Irish 3, Dutch 4, Swedish | c.2624del;p. Leu875Cysfs*20 | c.2593C>T;p.Arg865* | decreased                           | NP                                      | 2 wks          | Red      | Pale   | [12]|
| 3       | 51           | F   | Swiss    | c.1871T>G;p.Leu624Arg | c.3293C>T;pThr1098Ile | normal                             | NP                                      | 1 mo           | Brown    | Pale   | [12]|
| 4       | 43           | F   | Swiss (sister of Patient 3) | c.1871T>G;p.Leu624Arg | c.3293C>T;pThr1098Ile | normal                             | NP                                      | ND             | Brown    | Pale   | [12]|
| 5       | 21           | F   | English and Irish | c.879dup;p.Lys294Glnfs*6 | c.2928_2929dup;p. Thr977Argfs*15 | decreased                           | NP                                      | 6 wks          | Red      | Pale   | [12]|
| 6       | 38           | F   | Turkish  | c.888dup;p.His297Thrfs*3 | c.888dup;p.His297Thrfs*3 | NP                                  | NP                                      | ND             | ND       | ND     | [17]|
| 7       | 1            | M   | Mexican  | c.1423del;p.Leu475Serfs*37 | Not detected | NP                                  | decreased                             | +              | Brown    | ND     | [13]|
| 8       | 3            | M   | Cuban-Venezuelan | c.302_305del;p. Val101Glyfs*3 | c.1634+1G>A;p.Asp504Valfs*22 | NP                                  | decreased                             | +              | Brown    | ND     | [13]|
| 9       | 72           | M   | ND       | c.1423del;p.Leu475Serfs*37 | c.1423del;p.Leu475Serfs*37 | NP                                  | NP                                      | Early in life  | ND       | Pale   | [18]|
| 10      | 30           | M   | Arabian  | c.1618C>T;p.Gln540* | c.1618C>T;p.Gln540* | NP                                  | NP                                      | +              | ND       | Pale   | [19]|
| 11      | 20           | F   | Arabian  | c.1618C>T;p.Gln540* | c.1618C>T;p.Gln540* | NP                                  | NP                                      | +              | ND       | Pale   | [19]|
| 12      | 27           | M   | Turkish  | c.285-10A>G;p.Ser95_Gln96insSerCysSer | c.285-10A>G;p.Ser95_Gln96insSerCysSer | decreased expression of two shorter isoforms | decreased + Pale brown | Pale  | This study |

NP, Not performed; ND, not described

https://doi.org/10.1371/journal.pone.0173682.t001
In conclusion, we report a novel HPS5 splice site mutation in an individual with HPS. Molecular and cellular findings prove pathogenicity of the mutation and confirm the role of BLOC-2 in endo-lysosomal dynamics.

Supporting information

**S1 Fig. Immunoblotting for the BLOC-1,2,3 and AP-3 complexes in HPS5 patients and two different control dermal fibroblasts.** (A) Western blotting results showing the expression level of HPS-5 and the other interacting partners of BLOC-2 (HPS3 and HPS6) along with a representative protein from each HPS complex (HPS2 for AP-3 complex, HPS4 for BLOC-3 complex and HPS7 for BLOC-1 complex) in patients compared to control. Two different controls (Control-1 and Control-2) and two additional HPS-5 patients (HPS5-1 and HPS5-2) were included along with our proband. Images include markers above and below the target band with estimated molecular weights for each protein. The level of protein expression was normalized with β-actin (ACTB).

**S2 Fig. Distribution of endosomal markers in control and patient cells.** (A) Distribution pattern of organelle marker (EEA-1, upper panels; Rab 7, middle panels; and Rab11, lower panels) are shown in green Two control lines and three HPS-5 patients including proband were analyzed. Phalloidin (red) stains actin filament and highlights cell boundary and DAPI (blue) stains nucleus. Both lower magnification images and higher magnification images are shown. Of note, Rab11 shows less fluorescent intensity in the three patients compared to controls. (B) Quantification of Rab11 abundance by western blot in control and HPS-5 lines. β-actin (ACTB) was used for normalizing total protein amount. Three replicates for western blotting were done. (C) Graph showing the quantification of bands detected by western. Error bars represent standard error of means.

**Acknowledgments**

This work was supported by the Intramural Research Programs of the National Human Genome Research Institute and the National Eye Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.

**Author Contributions**

**Conceptualization:** JS TY NJT KJO BRG WAG MCVM.

**Data curation:** JS TY NJT ERN KJO BPB LH SAT DRA DC BRG WAG MCVM.

**Formal analysis:** JS TY NJT ERN BPB LH SAT DRA MCVM.

**Funding acquisition:** BRB WAG.

**Investigation:** JS TY NJT ERN KJO BPB LH DRA DC BRG WAG MCVM.

**Methodology:** JS TY NJT KJO SAT BRG WAG MCVM.

**Project administration:** BRG WAG MCVM.

**Resources:** JS TY NJT ERN KJO BPB LH DRA DC BRG WAG MCVM.

**Software:** SAT DRA BRG MCVM.
Supervision: WAG BRG MCVM.
Validation: JS TY NT ERN MCVM.
Visualization: JS TY NJT ERN KJO BPB LH DC BRG WAG MCVM.
Writing – original draft: JS TY NJT MCVM.
Writing – review & editing: JS TY NJT RN KJO BPB LH SAT DRA DC BRG WAG MCVM.

References

1. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959; 14(2):162–9. Epub 1959/02/01. PMID: 13618373
2. Wei AH, Li W. Hermansky-Pudlak syndrome: pigmentary and non-pigmentary defects and their pathogenesis. Pigment cell & melanoma research. 2013; 26(2):176–92. Epub 2012/11/23.
3. Huizing M, Helip-Wooley A, Westbrook W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet. 2008; 9:359–86. PubMed Central PMCID: PMC2755194. https://doi.org/10.1146/annurev.genom.9.081307.164303 PMID: 18544035
4. Dell’Angela EC, Ooi CE, Bonifacino JS. Beta3A-adaptin, a subunit of the adaptor-like complex AP-3. The Journal of biological chemistry. 1997; 272(24):15078–84. Epub 1997/06/13. PMID: 9182526
5. Gu F, Crump CM, Thomas G. Trans-Golgi network sorting. Cellular and molecular life sciences: CMLS. 2001; 58(8):1067–84. Epub 2001/09/01. PubMed Central PMCID: PMCPmc1424219. https://doi.org/10.1007/PL00000922 PMID: 11529500
6. Wei ML, Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res. 2006; 19(1):19–42. https://doi.org/10.1111/j.1600-0749.2005.00289.x PMID: 16420244
7. Di Pietro SM, Falcon-Perez JM, Dell’Angela EC. Characterization of BLOC-2, a complex containing the Hermansky-Pudlak syndrome proteins HPS3, HPS5 and HPS6. Traffic (Copenhagen, Denmark). 2004; 5(4):276–83. Epub 2004/03/20.
8. Nazarian R, Falcon-Perez JM, Dell’Angela EC. Biogenesis of lysosome-related organelles complex 3 (BLOC-3): a complex containing the Hermansky-Pudlak syndrome (HPS) proteins HPS1 and HPS4. Proc Natl Acad Sci U S A. 2003; 100(15):8770–5. Epub 2003/07/09. PubMed Central PMCID: PMCPmc166388. https://doi.org/10.1073/pnas.1532041100 PMID: 12847290
9. Rouhani FN, Brantly ML, Markello TC, Helip-Wooley A, Hess R, et al. Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1. American journal of respiratory and critical care medicine. 2009; 180(11):1114–21. PubMed Central PMCID: PMC2784416. https://doi.org/10.1164/rccm.200901-0023OC PMID: 19729668
10. Livak K. Comparative Ct method. ABI Prism 7700 Sequence Detection System. 1997.
11. Yu D, Swaroop M, Wang M, Baxa U, Yang R, Yan Y, et al. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. Journal of biomolecular screening. 2014; 19(8):1164–73. Epub 2014/06/08. PubMed Central PMCID: PMCPMC4529815. https://doi.org/10.1117/1087057114537378 PMID: 24907126
12. Huizing M, Hess R, Dorward H, Claassen DA, Helip-Wooley A, Kleta R, et al. Cellular, molecular and clinical characterization of patients with Hermansky-Pudlak syndrome type 5. Traffic (Copenhagen, Denmark). 2004; 5(9):711–22.
13. Carmona-Rivera C, Golas G, Hess RA, Cardillo ND, Martin EH, O’Brien K, et al. Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent. The Journal of investigative dermatology. 2011; 131(12):2394–400. Epub 2011/08/13. PubMed Central PMCID: PMCPmc3213276. https://doi.org/10.1038/jid.2011.228 PMID: 21833017
14. Bulterma JJ, Ambrosio AL, Burek CL, Di Pietro SM. BLOC-2, AP-3, and AP-1 proteins function in concert with Rab38 and Rab32 proteins to mediate protein trafficking to lysosome-related organelles. The Journal of biological chemistry. 2012; 287(23):19550–63. Epub 2012/04/19. PubMed Central PMCID: PMCPmc3365991. https://doi.org/10.1074/jbc.M112.351908 PMID: 22511774
15. Dennis MK, Mantezegaza AR, Snir OL, Tenza D, Acosta-Ruiz A, Delevoye C, et al. BLOC-2 targets recycling endosomal tubules to melanosomes for cargo delivery. The Journal of cell biology. 2015; 209(4):563–77. Epub 2015/05/27. PubMed Central PMCID: PMCPmc4442807. https://doi.org/10.1083/jcb.201410026 PMID: 26008744
16. Zhang Q, Zhao B, Li W, Oiso N, Novak EK, Rusiniak ME, et al. Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nature genetics. 2003; 33 (2):145–53. Epub 2003/01/28. https://doi.org/10.1038/ng1087 PMID: 12548288

17. Korswagen LA, Huizing M, Simsek S, Janssen JJ, Zweegman S. A novel mutation in a Turkish patient with Hermansky-Pudlak syndrome type 5. European journal of haematology. 2008; 80(4):356–60. Epub 2008/01/10. https://doi.org/10.1111/j.1600-0609.2007.01024.x PMID: 18182080

18. Ringeisen AL, Schimmendi LA, White JG, Schoonveld C, Summers CG. Hermansky-Pudlak syndrome (HPS5) in a nonagenarian. Journal of AAPOS: the official publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus. 2013; 17(3):334–6.

19. Khan AO, Tamimi M, Lenzner S, Bolz HJ. Hermansky-Pudlak syndrome genes are frequently mutated in patients with albinism from the Arabian Peninsula. Clinical genetics. 2016.